OptimizeRx Corp.

OPRX Healthcare Health Information Services

OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024. In the quarter to June 2026, revenue fell 29.8%, EPS fell 150.0%, free cash flow grew 89.9% and total debt fell 33.1%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

8.50 0.35 −3.95%
Market cap
$166.7M
P/E
35.4×
Fwd P/E
23.0×
Dividend yield
—
F-score
8/9
Altman Z
3.31
Beneish M
−2.77
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

0.03% 4.18% 5.56% 3.68%
Piotroski F-Score
7 8 8 7
ROA
0.02% 2.95% 4.08% 2.76%
ROIC
3.24% 5.60% 6.68% 5.41%
Return on Tangible Assets
0.09% 11.78% 14.92% 10.33%
Average Days of Receivables
113.24 128.43 111.73 100.35
Free Cash Flow per Share
0.62 1.01 0.77 0.99
Free Cash Flow
11.57 18.78 14.52 18.57
Capital Expenditures
(0.26) 0.07 0.13 0.14
Other line items
Cash ROIC
6.81% 10.59% 8.38% 10.66%
Accounts Receivable Turnover
3.63 2.85 3.27 3.22
Accounts Payable Turnover
15.86 18.90 9.98 15.99
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
19.57 16.66 34.80 18.28
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
(0.98) (0.26) (0.29) (0.32)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 13.20%
Selling, General and Administrative Expense of Revenue
49.35% 52.28% 52.33% 57.12%
Share Based Compensation of Revenue
7.25% 6.36% 6.74% 8.06%
Interest Coverage
1.21 2.21 2.75 2.33
Operating CF/Net income
358.33 3.65 2.10 4.01
Depreciation/Fixed assets
(17.42) 51.29 52.25 44.43
Capex/Depreciation
0.12 0.01 0.02 0.03
Revenue per Share
5.90 5.90 5.72 5.25
Operating CF per Share
0.64 1.01 0.77 0.98
Capex per Share
(0.01) 0.00 0.01 0.01
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates